Lacomblez L, Doppler V, Beucler I, Costes G, Salachas F, Raisonnier A, Le Forestier N, Pradat P-F, Bruckert E, Meininger V
Fédération de Neurologie Mazarin, Service de Pharmacologie, AP-HP, Hôpital de la Salpêtrière, Paris, France.
Neurology. 2002 Apr 9;58(7):1112-4. doi: 10.1212/wnl.58.7.1112.
Although documented in AD, the role of APOE remains unclear in ALS. APOE phenotype and plasma levels were measured in 403 patients with ALS and were correlated with clinical parameters and survival time. No correlations were observed between the APOE phenotype and these variables. In contrast, APOE plasma levels were correlated with both rate of deterioration and survival time and appeared to be an important risk factor for decreased survival time with a relative risk of 0.647 (95% CI: 0.465 to 0.901; p = 0.01).
尽管载脂蛋白E（APOE）在阿尔茨海默病（AD）中有相关记录，但其在肌萎缩侧索硬化症（ALS）中的作用仍不清楚。对403例ALS患者测量了APOE表型和血浆水平，并将其与临床参数和生存时间进行关联分析。未观察到APOE表型与这些变量之间存在相关性。相比之下，APOE血浆水平与病情恶化速度和生存时间均相关，并且似乎是生存时间缩短的一个重要风险因素，相对风险为0.647（95%置信区间：0.465至0.901；p = 0.01）。
